QGEN - QIAGEN N.V.

NYSE - NYSE Delayed Price. Currency in USD

36.66

+0.45 (+1.24%)

At close: 4:03PM EDT

Stock chart is not supported by your current browser

Previous Close	36.21
Open	36.65
Bid	36.57 x 800
Ask	36.64 x 2200
Day's Range	36.49 - 36.80
52 Week Range	30.20 - 37.61
Volume	1,512,576
Avg. Volume	863,806

Market Cap	8.326B
Beta	1.05
PE Ratio (TTM)	159.39
EPS (TTM)	0.23
Earnings Date	Jul 23, 2018 - Jul 27, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	36.86

Trade prices are not sourced from all markets

All

News

Press Releases

Simply Wall St.3 days ago
Should You Be Tempted To Sell QIAGEN NV (NYSE:QGEN) Because Of Its PE Ratio?
This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...
ACCESSWIRE4 days ago
Free Technical Reports on Myriad Genetics and Three Additional Services Equities
WallStEquities.com has initiated research reports on the following Services stocks: CareDx Inc. (CDNA), Myriad Genetics Inc. (MYGN), QIAGEN N.V. (QGEN), and Nxt-ID Inc. (NXTD). Brisbane, California headquartered CareDx Inc.'s stock finished Wednesday's session 5.51% lower at $14.74 with a total trading volume of 569,113 shares, which was higher than their three months average volume of 518.93 thousand shares. The Company's shares are trading above their 50-day and 200-day moving averages by 26.99% and 101.82%, respectively.
Zacks6 days ago
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Business Wire21 days ago
QIAGEN Welcomes New Guidelines from American Academy of Pediatrics for Detecting Tuberculosis Infection in Children
QIAGEN N.V. today announced that it welcomes new guidelines from the American Academy of Pediatrics that recommend screening at-risk children as young as two years old for latent tuberculosis infection.
Zacks24 days ago
Why Is QIAGEN (QGEN) Up 13.8% Since Its Last Earnings Report?
QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Business Wire24 days ago
QIAGEN showcases innovation in NGS solutions for precision medicine at ASCO 2018
QIAGEN N.V. today announced a partnership with Freenome, a leading artificial intelligence genomics company, to accelerate the development and commercialization of next-generation sequencing tests to enable precision medicine in cancer treatment.
Investor's Business Dailylast month
IBD Rating Upgrades: Qiagen Flashes Improved Relative Price Strength
A Relative Strength Rating upgrade for Qiagen shows improving technical performance. Will it continue?
Business Wirelast month
QIAGEN Welcomes WHO’s Essential Diagnostics List Which Includes QuantiFERON-TB Gold
QIAGEN today welcomed the First Edition of the World Health Organization’s (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection. The inclusion on the list comes as the WHO and other organizations like the US Centers for Disease Control (CDC), the International Panel Physicians Association (IPPA) and others have recommended to include IGRA’s such as QuantiFERON-TB Gold Plus. The World Health Organization (WHO) published the first edition of the Model List of Essential In Vitro Diagnostics (EDL) in May 2018, in recognition that IVDs are an essential component to advance universal health coverage, address health emergencies, and promote healthier populations.
Zackslast month
QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff
QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.
ACCESSWIRElast month
Canadian National Railway and Three Additional Services Stocks on Investors’ Radar
On Tuesday, May 15, 2018, US markets saw broad based losses with all sectors finishing the trading sessions in red. All you have to do is sign up today for this free limited time offer by clicking the link below.
Business Wirelast month
QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
Frankfurt Prime Standard: QIA) announces that it will initiate the repurchase of a first tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 15, 2018 until August 20, 2018, at the latest, a first tranche of up to 1.65 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of QGEN earnings conference call or presentation 3-May-18 1:00pm GMT
Q1 2018 Qiagen NV Earnings Call
Motley Fool2 months ago
Qiagen Starts Slowly but Is On Track
The launch of QIAstat-Dx should help accelerate growth in the second half of the year.
Zacks2 months ago
QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1
QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.
Associated Press2 months ago
Qiagen: 1Q Earnings Snapshot
The Venlo, Netherlands-based company said it had net income of 14 cents per share. Earnings, adjusted for non-recurring costs, came to 26 cents per share. The results beat Wall Street expectations. The ...
Business Wire2 months ago
QIAGEN Reports Results for First Quarter 2018
QIAGEN N.V. announced results of operations for the first quarter, exceeding goals for net sales and adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
Zacks2 months ago
Why QIAGEN (QGEN) Might Surprise This Earnings Season
QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
Business Wire2 months ago
QIAGEN Announces FDA Approval of PartoSureTM
QIAGEN N.V. today announced the U.S. regulatory approval of PartoSureTM , which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
Business Wire2 months ago
QIAGEN announces European launch of QIAstat-Dx®, a next generation platform for syndromic insights
QIAGEN N.V. today announced the launch of QIAstat-Dx® in Europe, providing a one-step, fully integrated molecular analysis of common syndromes as tested for in syndromes in infections, oncology and other diseases.
Business Wire2 months ago
QIAGEN posts 2017 Annual Report on Its website
QIAGEN N.V. announced today that has posted its 2017 Annual Report on its website at http://financialreport.qiagen.com.
Business Wire2 months ago
QIAGEN N.V. to Report First Quarter 2018 Results
QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2018 on Wednesday, May 2 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
Business Wire2 months ago
QIAGEN Launches AdnaTest Liquid Biopsy Kits in Prostate and Lung Cancer
QIAGEN N.V. today launched two novel liquid biopsy panels to evaluate circulating tumor cells in the growing field of research into molecular mechanisms in prostate and lung cancers.
Markit3 months ago
See what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGEN
Markit3 months ago
See what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGEN
Zacks3 months ago
QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening
QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.